Fredric L. Coe to Calcium Oxalate
This is a "connection" page, showing publications Fredric L. Coe has written about Calcium Oxalate.
Connection Strength
8.629
-
Evidence for disordered acid-base handling in calcium stone-forming patients. Am J Physiol Renal Physiol. 2020 02 01; 318(2):F363-F374.
Score: 0.653
-
Contrasting histopathology and crystal deposits in kidneys of idiopathic stone formers who produce hydroxy apatite, brushite, or calcium oxalate stones. Anat Rec (Hoboken). 2014 Apr; 297(4):731-48.
Score: 0.436
-
Pathophysiology-based treatment of idiopathic calcium kidney stones. Clin J Am Soc Nephrol. 2011 Aug; 6(8):2083-92.
Score: 0.367
-
Comparison of the pathology of interstitial plaque in human ICSF stone patients to NHERF-1 and THP-null mice. Urol Res. 2010 Dec; 38(6):439-52.
Score: 0.349
-
Three pathways for human kidney stone formation. Urol Res. 2010 Jun; 38(3):147-60.
Score: 0.336
-
Evidence against a contribution of conventional urine risk factors to de novo ESRD renal stones. Nephrol Dial Transplant. 2006 Mar; 21(3):701-6.
Score: 0.248
-
Influence of gender and age on calcium oxalate crystal growth inhibition by urine from relatives of stone forming patients. J Urol. 2002 Jun; 167(6):2372-6.
Score: 0.194
-
Stone Morphology Distinguishes Two Pathways of Idiopathic Calcium Oxalate Stone Pathogenesis. J Endourol. 2022 05; 36(5):694-702.
Score: 0.193
-
Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats. Kidney Int. 2002 Mar; 61(3):975-87.
Score: 0.191
-
Proportional reduction of urine supersaturation during nephrolithiasis treatment. J Urol. 2001 Oct; 166(4):1247-51.
Score: 0.185
-
In Vivo Renal Tubule pH in Stone-Forming Human Kidneys. J Endourol. 2020 02; 34(2):203-208.
Score: 0.165
-
Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int. 1999 Oct; 56(4):1505-16.
Score: 0.161
-
Divergence between stone composition and urine supersaturation: clinical and laboratory implications. J Urol. 1999 Apr; 161(4):1077-81.
Score: 0.156
-
Randall's plaque in stone formers originates in ascending thin limbs. Am J Physiol Renal Physiol. 2018 11 01; 315(5):F1236-F1242.
Score: 0.149
-
Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol. 1998 08; 275(2):F255-61.
Score: 0.149
-
Metabolic urinary correlates of calcium oxalate dihydrate in renal stones. J Urol. 1998 Mar; 159(3):664-8.
Score: 0.145
-
Normal calcium oxalate crystal growth inhibition in severe calcium oxalate nephrolithiasis. J Am Soc Nephrol. 1996 Apr; 7(4):602-7.
Score: 0.127
-
Nephrocalcinosis in Calcium Stone Formers Who Do Not have Systemic Disease. J Urol. 2015 Nov; 194(5):1308-12.
Score: 0.119
-
Biopsy proven medullary sponge kidney: clinical findings, histopathology, and role of osteogenesis in stone and plaque formation. Anat Rec (Hoboken). 2015 May; 298(5):865-77.
Score: 0.117
-
An increasing number of calcium oxalate stone events worsens treatment outcome. Kidney Int. 1994 Jun; 45(6):1722-30.
Score: 0.112
-
Calcium restriction, thiazide, citrate, and allopurinol in calcium oxalate nephrolithiasis. Acta Urol Belg. 1994 Jun; 62(2):25-9.
Score: 0.112
-
Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis. Miner Electrolyte Metab. 1994; 20(6):378-84.
Score: 0.108
-
A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I. Am J Physiol Renal Physiol. 2013 Dec 01; 305(11):F1574-84.
Score: 0.107
-
Nephrocalcin: biosynthesis by human renal carcinoma cells in vitro and in vivo. Cancer Res. 1992 Mar 15; 52(6):1573-9.
Score: 0.096
-
Urine risk factors in children with calcium kidney stones and their siblings. Kidney Int. 2012 Jun; 81(11):1140-8.
Score: 0.095
-
Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol. 1991 Nov; 261(5 Pt 2):F824-30.
Score: 0.093
-
Inhibitors within the nephron. Am J Kidney Dis. 1991 Apr; 17(4):407-13.
Score: 0.090
-
Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol. 1991 Apr; 260(4 Pt 2):F569-78.
Score: 0.090
-
Isolation of nephrocalcin from kidney tissue of nine vertebrate species. Am J Physiol. 1991 Feb; 260(2 Pt 2):F243-8.
Score: 0.089
-
Clinical practice. Calcium kidney stones. N Engl J Med. 2010 Sep 02; 363(10):954-63.
Score: 0.086
-
Renal histopathology and crystal deposits in patients with small bowel resection and calcium oxalate stone disease. Kidney Int. 2010 Aug; 78(3):310-7.
Score: 0.084
-
Evidence that mouse renal proximal tubule cells produce nephrocalcin. Am J Physiol. 1989 Sep; 257(3 Pt 2):F390-8.
Score: 0.080
-
Elucidation of multiple forms of nephrocalcin by 31P-NMR spectrometer. FEBS Lett. 1989 Jul 03; 250(2):187-90.
Score: 0.079
-
Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol. 1989 Jul; 257(1 Pt 2):F99-106.
Score: 0.079
-
Gestational hypercalciuria causes pathological urine calcium oxalate supersaturations. Kidney Int. 1989 Jul; 36(1):108-13.
Score: 0.079
-
In idiopathic calcium oxalate stone-formers, unattached stones show evidence of having originated as attached stones on Randall's plaque. BJU Int. 2010 Jan; 105(2):242-5.
Score: 0.079
-
Crystal adsorption and growth slowing by nephrocalcin, albumin, and Tamm-Horsfall protein. Am J Physiol. 1988 Dec; 255(6 Pt 2):F1197-205.
Score: 0.076
-
A formal test of the hypothesis that idiopathic calcium oxalate stones grow on Randall's plaque. BJU Int. 2009 Apr; 103(7):966-71.
Score: 0.076
-
Evidence for durable kidney stone prevention over several decades. BJU Int. 2009 May; 103(9):1238-46.
Score: 0.076
-
Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney Int. 1988 Jun; 33(6):1140-6.
Score: 0.074
-
Renal intratubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones. Anat Rec (Hoboken). 2008 Mar; 291(3):325-34.
Score: 0.072
-
Role of interstitial apatite plaque in the pathogenesis of the common calcium oxalate stone. Semin Nephrol. 2008 Mar; 28(2):111-9.
Score: 0.072
-
Mechanism of formation of human calcium oxalate renal stones on Randall's plaque. Anat Rec (Hoboken). 2007 Oct; 290(10):1315-23.
Score: 0.070
-
Renal inter-alpha-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients. Kidney Int. 2007 Dec; 72(12):1503-11.
Score: 0.070
-
Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid. J Clin Invest. 1987 Jun; 79(6):1782-7.
Score: 0.069
-
Glycoprotein calcium oxalate crystal growth inhibitor in urine. Miner Electrolyte Metab. 1987; 13(4):267-72.
Score: 0.067
-
The role of Randall's plaques in the pathogenesis of calcium stones. J Urol. 2007 Jan; 177(1):31-8.
Score: 0.067
-
Pathophysiological correlates of two unique renal tubule lesions in rats with intestinal resection. Am J Physiol Renal Physiol. 2006 Nov; 291(5):F1061-9.
Score: 0.066
-
Evidence that serum calcium oxalate supersaturation is a consequence of oxalate retention in patients with chronic renal failure. J Clin Invest. 1986 Jun; 77(6):1888-96.
Score: 0.064
-
Endoscopic evidence of calculus attachment to Randall's plaque. J Urol. 2006 May; 175(5):1720-4; discussion 1724.
Score: 0.064
-
Urine protein markers distinguish stone-forming from non-stone-forming relatives of calcium stone formers. Am J Physiol Renal Physiol. 2006 Sep; 291(3):F530-6.
Score: 0.064
-
Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int. 2006 Apr; 69(8):1313-8.
Score: 0.063
-
Kidney stone disease. J Clin Invest. 2005 Oct; 115(10):2598-608.
Score: 0.061
-
Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis. J Clin Invest. 1985 Oct; 76(4):1455-62.
Score: 0.061
-
Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int. 2005 Jul; 68(1):145-54.
Score: 0.060
-
Isolation of calcium oxalate crystal growth inhibitor from rat kidney and urine. Am J Physiol. 1984 Nov; 247(5 Pt 2):F765-72.
Score: 0.057
-
Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab. 2004 Oct; 89(10):4937-43.
Score: 0.057
-
Urine calcium and volume predict coverage of renal papilla by Randall's plaque. Kidney Int. 2003 Dec; 64(6):2150-4.
Score: 0.054
-
Endoscopic renal papillary biopsies: a tissue retrieval technique for histological studies in patients with nephrolithiasis. J Urol. 2003 Dec; 170(6 Pt 1):2186-9.
Score: 0.054
-
Uric acid and calcium oxalate nephrolithiasis. Kidney Int. 1983 Sep; 24(3):392-403.
Score: 0.053
-
A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease. Nat Commun. 2023 07 19; 14(1):4140.
Score: 0.053
-
Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int. 2003 Jan; 63(1):255-65.
Score: 0.051
-
Clinical Effectiveness of Calcium Oxalate Stone Treatments. Am J Nephrol. 2022; 53(10):761-766.
Score: 0.050
-
Pathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis. Kidney Int. 1982 Oct; 22(4):366-70.
Score: 0.050
-
What treatments reduce kidney stone risk in patients with bowel disease? Urolithiasis. 2022 Oct; 50(5):557-565.
Score: 0.049
-
Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int. 2002 May; 61(5):1821-9.
Score: 0.048
-
Differences in urine volume and supersaturation in 2 physician networks. J Urol. 2001 Aug; 166(2):423-8.
Score: 0.046
-
Clinical characteristics and pathogenetic mechanisms in hyperuricosuric calcium oxalate renal stone disease. Scand J Urol Nephrol Suppl. 1980; 53:171-7.
Score: 0.041
-
Hyperuricosuric calcium oxalate nephrolithiasis. Adv Exp Med Biol. 1980; 128:439-50.
Score: 0.041
-
Increased dietary oxalate does not increase urinary calcium oxalate saturation in hypercalciuric rats. Kidney Int. 1999 Feb; 55(2):602-12.
Score: 0.039
-
Isolation and characterization of calcium oxalate crystal growth inhibitors from human urine. Biochem Biophys Res Commun. 1978 Oct 30; 84(4):1038-44.
Score: 0.038
-
Supersaturation and stone composition in a network of dispersed treatment sites. J Urol. 1998 Jun; 159(6):1821-5.
Score: 0.037
-
Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int. 1998 Jan; 53(1):194-9.
Score: 0.036
-
Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int. 1997 Dec; 52(6):1602-8.
Score: 0.036
-
Relationship between supersaturation and crystal inhibition in hypercalciuric rats. Kidney Int. 1997 Mar; 51(3):640-5.
Score: 0.034
-
Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int. 1997 Mar; 51(3):894-900.
Score: 0.034
-
Increased urinary saturation and kidney calcium content in genetic hypercalciuric rats. Kidney Int. 1994 Jan; 45(1):58-65.
Score: 0.027
-
Nephrocalcinosis: re-defined in the era of endourology. Urol Res. 2010 Dec; 38(6):421-7.
Score: 0.022
-
Defenses of an unstable compromise: crystallization inhibitors and the kidney's role in mineral regulation. Kidney Int. 1990 Oct; 38(4):625-31.
Score: 0.022
-
Intra-tubular deposits, urine and stone composition are divergent in patients with ileostomy. Kidney Int. 2009 Nov; 76(10):1081-8.
Score: 0.020
-
A test of the hypothesis that the collecting duct calcium-sensing receptor limits rise of urine calcium molarity in hypercalciuric calcium kidney stone formers. Am J Physiol Renal Physiol. 2009 Oct; 297(4):F1017-23.
Score: 0.020
-
A new spectrophotometric method for measuring calcium oxalate monohydrate crystal aggregation in the absence of supersaturation: inhibitory effects of urinary glycoproteins. Urol Res. 1989; 17(3):149-50.
Score: 0.019
-
Clinical and laboratory characteristics of calcium stone-formers with and without primary hyperparathyroidism. BJU Int. 2009 Mar; 103(5):670-8.
Score: 0.019
-
Urine pH in renal calcium stone formers who do and do not increase stone phosphate content with time. Nephrol Dial Transplant. 2009 Jan; 24(1):130-6.
Score: 0.019
-
Pathophysiology of kidney stones and strategies for treatment. Hosp Pract (Off Ed). 1988 Mar 15; 23(3):185-9, 193-5, 199-200 passim.
Score: 0.018
-
The pathogenesis of calyceal diverticular calculi. Urol Res. 2007 Feb; 35(1):35-40.
Score: 0.017
-
Immunochemistry of urinary calcium oxalate crystal growth inhibitor (CGI). Kidney Int. 1986 Apr; 29(4):829-33.
Score: 0.016
-
Recurrent renal calculi. Causes and prevention. Hosp Pract (Off Ed). 1986 Mar 30; 21(3A):49-57.
Score: 0.016
-
Urine citrate and calcium in calcium nephrolithiasis. Adv Exp Med Biol. 1986; 208:445-9.
Score: 0.016
-
Insights on the pathology of kidney stone formation. Urol Res. 2005 Nov; 33(5):383-9.
Score: 0.015
-
Stone formation is proportional to papillary surface coverage by Randall's plaque. J Urol. 2005 Jan; 173(1):117-9; discussion 119.
Score: 0.015
-
Molecular abnormality of urinary glycoprotein crystal growth inhibitor in calcium nephrolithiasis. Trans Assoc Am Physicians. 1985; 98:281-9.
Score: 0.015
-
Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. J Biol Chem. 1983 Oct 25; 258(20):12594-600.
Score: 0.013
-
Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest. 2003 Mar; 111(5):607-16.
Score: 0.013
-
Hyperuricosuria and calcium nephrolithiasis. Urol Clin North Am. 1981 Jun; 8(2):227-44.
Score: 0.011
-
Purification and characterization of a calcium oxalate monohydrate crystal growth inhibitor from human kidney tissue culture medium. J Biol Chem. 1981 Apr 25; 256(8):3936-44.
Score: 0.011
-
Nephrolithiasis: causes, classification, and management. Hosp Pract (Hosp Ed). 1981 Apr; 16(4):33-45.
Score: 0.011
-
Uric acid saturation in calcium nephrolithiasis. Kidney Int. 1980 May; 17(5):662-8.
Score: 0.011
-
The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers. Scand J Urol Nephrol Suppl. 1980; 53:265-71.
Score: 0.010
-
Urinary saturation measurements in calcium nephrolithiasis. Ann Intern Med. 1979 Feb; 90(2):180-4.
Score: 0.010